Suchergebnisse - "Clinical Trial, Phase III"

PubPharm (530)

1

Bone Biomarkers and Subsequent Survival in Men with Hormone-sensitive Prostate Cancer : Results from the SWOG S1216 Phase 3 Trial of Androgen Deprivation Therapy with or Without Orteronel

enthalten in: European urology | 2024

von Lara, P. | Mayerson, E. | Gertz, E. | +13

2

Metastatic Colorectal Cancer Treatment Response Evaluation by Ultra-Deep Sequencing of Cell-Free DNA and Matched White Blood Cells

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2023

von van 't Erve, I. | Medina, J. | Leal, A. | +16

3

Pertuzumab, trastuzumab, and chemotherapy in HER2-positive gastric/gastroesophageal junction cancer : end-of-study analysis of the JACOB phase III randomized clinical trial

enthalten in: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association | 2023

von Tabernero, J. | Hoff, P. | Shen, L. | +8

CommentOn: Lancet Oncol. 2018 Oct;19(10):1372-1384. - PMID 30217672

4

Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer : an open-label, phase III study (KRISTINE)

enthalten in: Breast cancer research : BCR | 2023

von de Haas, S. | Slamon, D. | Martin, M. | +7

5

External Validation of Association of Baseline Circulating Tumor Cell Counts with Survival Outcomes in Men with Metastatic Castration-Sensitive Prostate Cancer

enthalten in: Molecular cancer therapeutics | 2022

von Swami, U. | Sayegh, N. | Jo, Y. | +9

6

Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden : primary analysis of BFAST cohort C randomized phase 3 trial

enthalten in: Nature medicine | 2022

von Peters, S. | Dziadziuszko, R. | Morabito, A. | +23

CommentIn: Nat Med. 2022 Sep;28(9):1753-1754. - PMID 36097224

7

Association of Tumor Mutational Burden with Efficacy of Pembrolizumab±Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2022

von Lee, K. | Van Cutsem, E. | Bang, Y. | +17

8

Gastric cancer biomarker analysis in patients treated with different adjuvant chemotherapy regimens within SAMIT, a phase III randomized controlled trial

enthalten in: Scientific reports | 2022

von Oshima, T. | Tsuburaya, A. | Yoshida, K. | +9

9

Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer : Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2022

von Bellmunt, J. | de Wit, R. | Fradet, Y. | +28

CommentIn: J Urol. 2023 May;209(5):1025-1026. - PMID 37026649

10

Response prediction and risk stratification of patients with rectal cancer after neoadjuvant therapy through an analysis of circulating tumour DNA

enthalten in: EBioMedicine | 2022

von Liu, W. | Li, Y. | Tang, Y. | +10

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[53]